Why has the stock fallen back?
Results for the quarter were in line with analysts’ expectations. Investors were initially delighted with the growth figures for Wegovy, the Group’s weight-loss drug, which did not disappoint, unlike Eli Lilly’s treatments in this indication. Sales of Wegovy soared by…
© MarketScreener.com 2024
Results for the quarter were in line with analysts’ expectations. Investors were initially delighted with the growth figures for Wegovy, the Group’s weight-loss drug, which did not disappoint, unlike Eli Lilly’s treatments in this indication. Sales of Wegovy soared by…
© MarketScreener.com 2024